Read + Share
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, et al. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of
idelalisib for relapsed indolent lymphomas. Leuk Lymphoma 2021;62:1077-1087.
PMID: 33300385
|
 |
|
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, et al. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of
idelalisib for relapsed indolent lymphomas. Leuk Lymphoma 2021;62:1077-1087.
PMID: 33300385
|
|
|
|